Agios Pharmaceuticals was founded by Lewis Cantley Ph.D., (Harvard Medical School), Craig Thompson M.D. (University of Pennsylvania), Tak Wah Mak Ph.D. (University of Toronto), and Michael Su Ph.D. (formerly Novartis and BEL) to develop therapeutics for cancer and possibly other diseases based on novel insights in cell metabolism. The founders are all internationally regarded leaders in their fields and their idea is exciting and transformative. Agios’ science has already produced multiple publications in the most prestigious journals (Science, Cell, Nature) and plenary speeches at the largest scientific meetings. Flagship General Partner Doug Cole is on the Board.

www.agiospharma.com